Citadel Advisors
AIDX

Citadel Advisors’s 20/20 Biolabs Inc AIDX Stock Holding History

Citadel Advisors’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Buy
+16,227
New +$68.5K ﹤0.01% 12566

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Citadel Advisors's AIDX Position: Q1 2026 in Review

Citadel Advisors opened a new position in 20/20 Biolabs Inc (AIDX) in Q1 2026: 16,227 shares worth $30.5K. The stake represents ﹤0.01% of the portfolio and ranks #12566 among its holdings.

7 funds tracked by Wall St. Rank hold AIDX as of Q1 2026.

  • Citadel Advisors held 16,227 shares of 20/20 Biolabs Inc worth $30.5K as of Q1 2026.
  • 20/20 Biolabs Inc was a new Citadel Advisors position in Q1 2026.
  • 20/20 Biolabs Inc made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12566 holding.
  • 7 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.